Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report ongoing study by Infinium Global Research on the achalasia treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional achalasia treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional achalasia treatment market over the short term as well as the long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the global achalasia treatment market. According to the report, the global achalasia treatment market is projected to grow at a healthy CAGR over the forecast period of 2021-2027.
Achalasia cardia is one of the neurodegenerative disorders of the esophagus making the passage of food difficult. It is a disease with unknown causes but few genetic factors, as well as neuromuscular disorders, are been linked to this disease it has higher unmet needs in the possibly best achalasia treatment. Achalasia affects the lower part of the esophagus and lowers the food passing capacity by tightening the muscles around the esophagus. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia, and postprandial aspiration, among others. Achalasia affects adults aged between 25 and 60 years. It is also considered that it is likely to occur at any age, including the child age group population also. 10 in every 100,000 of the general population in the United States are affected by this disorder The COVID-19 outbreak had a significant impact on the chemicals and accouterments sectors across the world. Strict lockdown majorly reflected in a reduction in supply for raw materials supply and its availability, which directly affected the manufacturing process. Moreover, many industries had to shut down their manufacturing units due to a shortage of laborers which directly affected the chemical demand around the world. All the other treatments and drug approvals were delayed due to the demand for COVID-19 treatment increased globally creating fear amongst the population. This has affected the global achalasia treatment market as many have stopped manufacturing units as the demand decreased during the covid times.
As achalasia affects the older age group population more as compared to the younger age group population, the aging population is expected to drive the growth of the achalasia treatment market. Increasing research fundings and R&D expenditure from the governments is driving the growth of the global achalasia treatment market. Moreover, there is inadequate treatment information among healthcare providers about achalasia is expected to restrain the global achalasia treatment market. As this is a rare disorder awareness and understanding are often low and several patients are struggling to find adequate information related to it which can hamper its growth in the market in forecasting years. The studies carried out for the assessment of the achalasia treatment in western countries further limit the potential growth of the achalasia treatment market.
Among the regions, the North
American region accounted for the largest share in the global Achalasia Treatment Market. Factors such as
better health care infrastructure, economic growth, rise in the number of
insurance payers, expanding and developing private health care sector, and
increase in awareness among people regarding achalasia diagnostic and treatment
are expected to boost the market in this region. However, the Asia Pacific
region is anticipated to grow with the highest rate in the Achalasia Treatment
Market over the forecast accounted for the largest share in the global
Achalasia Treatment market period. Due to the entry of new players in the
region and increasing awareness about achalasia treatment is expected to grow
its market. The Middle East & Africa hold a minimum market share in the
global achalasia treatment market owing to a lack of strategies for access to
treatments for achalasia.
The report on the global achalasia treatment market covers segments such as drug type, non-surgical treatment, surgical treatment, and distribution channel. On the basis of drug type, the sub-markets include nitrates, calcium channel blockers (CCBs), botulinum toxin, and others. On the basis of non-surgical treatment, the sub-markets include botulinum toxin type A, pneumatic dilation, and others. On the basis of surgical treatment, the sub-markets include peroral endoscopic myotomy (POEM), heller myotomy, and others. On the basis of distribution channel, the sub-markets include retail pharmacies, hospital pharmacies, and online pharmacies.
The report provides profiles of the companies in the market such as Pfizer Inc., Bausch Health US LLC, Sun Pharma Industries Ltd, Zydus Pharmaceuticals (USA) Inc, Accordhealthcare, AdvaCare Pharma, Merz Therapeutics, XION GmbH, PENTAX Medical, and Teva pharmaceutical industries ltd.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the achalasia treatment market. Moreover, the study highlights current
market trends and provides forecasts from 2021-2027. We also have highlighted
future trends in the market that will affect the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players.
Please Choose One of them.